Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08FKX
|
|||
| Former ID |
DCL000981
|
|||
| Drug Name |
SDZ-MAR-327
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Psychotic disorder [ICD-11: 6A20-6A25] | Phase 2 | [1], [2] | |
| Schizophrenia [ICD-11: 6A20] | Terminated | [1] | ||
| Company |
Novartis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H33N3O
|
|||
| Canonical SMILES |
CCC(C)(CC)C(=O)NC1CC2C(CC3=C(NC4=CC=CC2=C34)C)N(C1)C
|
|||
| InChI |
1S/C23H33N3O/c1-6-23(4,7-2)22(27)25-15-11-18-16-9-8-10-19-21(16)17(14(3)24-19)12-20(18)26(5)13-15/h8-10,15,18,20,24H,6-7,11-13H2,1-5H3,(H,25,27)/t15-,18?,20+/m0/s1
|
|||
| InChIKey |
UXRWQKITDPCICD-BEHPGTHXSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
| REF 2 | Positron emission tomographic analysis of central dopamine D1 receptor binding in normal subjects treated with the atypical neuroleptic, SDZ MAR 327. Int J Mol Med. 1998 Jan;1(1):243-7. | |||
| REF 3 | DOI: 10.1038/sj.mp.4002062 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.